A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Platinum-resistant Recurrent Ovarian Cancer Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Ovarian Epithelial
Ovarian Neoplasms
Platinum-resistant Recurrent Ovarian Cancer
Recurrence

Clinical Trial Details

NCT number	NCT06434610
Study type	Interventional
Source	Shanghai Jiaolian Drug Research and Development Co., Ltd
Contact	Xiaohua Wu
Phone	0086-021-64175590
Email	JJYIN555@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	June 30, 2024
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04720807` - Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer	Phase 2
Terminated	`NCT03642990` - NR in Chemo-induced Peripheral Neuropathy	Phase 2
Recruiting	`NCT03699449` - An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)	Phase 2
Active, not recruiting	`NCT04348032` - Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer	Phase 2
Recruiting	`NCT05325229` - A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer	Phase 2